Watson Settles Patent Litigation With Teva
Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the US patents covering Seasonale and Watson will continue marketing its generic equivalent product Quasense (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg). Watson further admits that the licensed patents are valid and enforceable.
On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the US District Court for the District of New Jersey involving Watson's Quasense product, which is a generic equivalent of Teva's Seasonale.
Will the move benefit Watson?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.